Neptune and Acasti Welcome Professor William Harris to Acasti's Scientific Advisory Board
April 20 2010 - 6:30AM
Neptune Technologies & Bioressources Inc. ("Neptune")
(Nasdaq:NEPT) (TSX-V:NTB) and Acasti Pharma Inc. ("Acasti") are
pleased to announce a further expansion of Acasti's Scientific
Advisory Board (SAB) by welcoming Dr. William S. Harris, PhD, who
is joining the current renowned members Pr S Nissen (Cleveland
Clinic), Pr Thomas G. Hartman (Rutgers University Center), Dr.
Magdy M. Abdel-Malik (Quaestio Global Partners).
Dr. Harris, an internationally recognized expert on omega-3
fatty acids, is a PhD in Nutritional Biochemistry, Research
Professor (Departments of Internal Medicine, University of South
Dakota), Senior Scientist and Director at the Cardiovascular Health
Research Center (Sandford Research/USD Sioux Falls). Over the
last 30 years, Dr. Harris has published over 180 scientific
articles on omega-3s, including his revolutionary work which first
proposed the Omega-3 Index as a cardiovascular risk factor. He has
also co-authored the America Heart Association's scientific
landmark statement, "Fish Consumption, Fish Oil, Omega-3 Fatty
Acids and Cardiovascular Disease," published in 2002 in the
journal Circulation. He has been the principal
investigator on 5 omega-3 related National Institutes of Health
(NIH) grants, and the co-developer of the Omega-3 Index as a new
risk factor for cardiovascular and neurocognitive disease in
Framingham and the Women's Health Initiative.
"Acasti is delighted to welcome Dr. Harris, as an active member
of our SAB. He brings valuable expertise in the field of omega-3
research in cardiometabolic and neurodegenerative conditions," said
Dr. Tina Sampalis, President of Acasti Pharma Inc. "Given the
positive feedback we have received from the Center for Drug
Evaluation and Research, Dr. Harris' participation in the SAB is
coming at the most opportune time. We are all very excited and
looking forward to benefiting from the advice of our SAB members
who are internationally recognized amongst the best in the
cardiovascular field," she added.
"I am excited to join the Acasti SAB, as I am particularly
impressed with the emphasis that the company puts into research in
qualifying the role and function of omega-3's in the management of
dyslipidemia and cardiovascular risks," said Dr. Harris. "It
is exciting to be involved in the initial development steps of what
may prove to be the next omega-3 lipid modulator," he added.
About Neptune Technologies & Bioressources
Inc.
Neptune is an industry-recognized leader in the innovation,
production and formulation of science-based and clinically proven
novel phospholipid products for the nutraceutical and
pharmaceutical markets. The Company focuses on growing consumer
health markets including cardiovascular, inflammatory and
neurological diseases driven by consumers taking a more proactive
approach to managing health and preventing disease. The Company
sponsors clinical trials aimed to demonstrate its product health
benefits and to obtain regulatory approval for label health claims.
Neptune is continuously expanding its intellectual property
portfolio as well as clinical studies and regulatory approvals.
Neptune's products are marketed and distributed in over 20
countries worldwide.
About Acasti Pharma Inc.
Acasti Pharma is developing a product portfolio of proprietary
novel long-chain omega-3 phospholipids. Phospholipids are the
major component of cell membranes and are essential for all vital
cell processes. They are one of the principal constituents of High
Density Lipoprotein (good cholesterol) and, as such, play an
important role in modulating cholesterol efflux. Acasti Pharma's
proprietary novel phospholipids carry and functionalize the
polyunsaturated omega-3 fatty acids EPA and DHA, which have been
shown to have substantial health benefits and which are stabilized
by potent antioxidants. Acasti Pharma is focusing initially on
treatments for chronic cardiovascular conditions within the
over-the-counter, medical food and prescription drug markets.
About NeuroBioPharm
NeuroBioPharm is pursuing pharmaceutical neurological
applications, and a clinical study for a medical food product with
a multinational partner is already initiated. The development of a
prescription drug candidate is currently in progress. Advanced
clinical development and commercialization is planned to be carried
out with multinational partners.
"Neither Nasdaq nor the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release."
Statements in this press release that are not statements of
historical or current fact constitute "forward-looking
statements" within the meaning of the U.S. Private
Securities Litigation Reform Act of 1995 and Canadian securities
laws. Such forward-looking statements involve known
and unknown risks, uncertainties, and other unknown factors that
could cause the actual results of the Company to be
materially different from historical results or from any future
results expressed or implied by such forward-looking
statements. In addition to statements which explicitly describe
such risks and uncertainties, readers are urged to
consider statements labeled with the terms "believes," "belief,"
"expects," "intends," "anticipates," "will," or
"plans" to be uncertain and forward-looking. The forward-looking
statements contained herein are also subject generally
to other risks and uncertainties that are described from time to
time in the Company's reports filed with the
Securities and Exchange Commission and the Canadian
securities commissions.
CONTACT: Neptune Technologies & Bioressources Inc.
Andre Godin, V.P. Administration and Finance
+1 450.687.2262
a.godin@neptunebiotech.com
www.neptunebiotech.com
Acasti Pharma Inc.
Dr. Tina Sampalis, President
+1 450.686.4555
t.sampalis@acastipharma.com
www.acastipharma.com
![](http://www.globenewswire.com/newsroom/ti?nf=MTYwIzE4OTE2NCMxMTg0OA==)
New Tymbal Resources (TSXV:NTB)
Historical Stock Chart
From Jun 2024 to Jul 2024
New Tymbal Resources (TSXV:NTB)
Historical Stock Chart
From Jul 2023 to Jul 2024